Karyopharm Therapeutics Share Price (NASDAQ: KPTI)

$6.3

▲

0.28

(4.65%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Karyopharm Therapeutics Stock chart to analyse performance

Karyopharm Therapeutics stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$6.10
Today's High:$6.45
$6.30
3.17%
Downside
Day's Volatility :5.43%
Upside
2.33%
52 Weeks Low:$3.51
52 Weeks High:$16.95
$6.30
44.29%
Downside
52 Weeks Volatility :79.29%
Upside
62.83%

Karyopharm Therapeutics Stock Returns

Period	Karyopharm Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	40.0%	6.0%	0.0%
6 Months	-28.66%	-6.4%	0.0%
1 Year	-48.27%	-11.1%	0.0%
3 Years	-92.56%	6.7%	-8.6%

Karyopharm Therapeutics Inc Key Stats

Check Karyopharm Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$6.02
Open	$6.26
Today's High	$6.45
Today's Low	$6.1
Market Capitalization	$52.2M
Today's Volume	$112.2K
52 Week High	$16.95
52 Week Low	$3.51
Revenue TTM	$137.3M
EBITDA	$-114.9M
Earnings Per Share (EPS)	$-14.84
Profit Margin	-90.02%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-891.05%

Stock Returns calculator for Karyopharm Therapeutics Stock including INR - Dollar returns

The Karyopharm Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Karyopharm Therapeutics investment value today

Current value as on today

₹55,452

Returns

₹44,548

(-44.55%)

Returns from Karyopharm Therapeutics Stock

₹48,864 (-48.86%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Karyopharm Therapeutics Stock

23%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Karyopharm Therapeutics Stock from India on INDmoney has increased by 23% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Karyopharm Therapeutics Inc

Name
Holdings %
Name
Holdings %
T. Rowe Price Investment Management,Inc.
8.43%
Vanguard Group Inc
5.99%
Adage Capital Partners Gp LLC
4.87%
Eversept Partners, LLC
2.97%
BlackRock Inc
2.81%
Citadel Advisors Llc
2.39%

Analyst Recommendation on Karyopharm Therapeutics Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Karyopharm Therapeutics(by analysts ranked 0 to 5 stars)

Karyopharm Therapeutics Share Price Target

What analysts predicted

Upside of 311.38%

Target:

$25.92

Current:

$6.30

Karyopharm Therapeutics share price target is $25.92, a slight Upside of 311.38% compared to current price of $6.30 as per analysts' prediction.

Karyopharm Therapeutics Stock Insights

Price Movement
In the last 1 month, KPTI stock has moved up by 43.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 30.01M → 37.92M (in $), with an average increase of 20.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -23.46M → -37.25M (in $), with an average decrease of 58.8% per quarter
KPTI vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 115.7%
KPTI vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 105.6% return, outperforming this stock by 198.3%
Price to Sales
ForKPTI every $1 of sales, investors are willing to pay $0.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Karyopharm Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$40.9M	↑ 34.8%
Net Income	$-199.6M	↑ 11.87%
Net Profit Margin	-488.08%	↑ 100.02%

	FY20	Y/Y Change
Revenue	$108.1M	↑ 164.31%
Net Income	$-196.3M	↓ 1.66%
Net Profit Margin	-181.59%	↑ 306.49%

	FY21	Y/Y Change
Revenue	$209.8M	↑ 94.12%
Net Income	$-124.1M	↓ 36.78%
Net Profit Margin	-59.14%	↑ 122.45%

	FY22	Y/Y Change
Revenue	$157.1M	↓ 25.14%
Net Income	$-165.3M	↑ 33.2%
Net Profit Margin	-105.23%	↓ 46.09%

	FY23	Y/Y Change
Revenue	$146.0M	↓ 7.03%
Net Income	$-143.1M	↓ 13.43%
Net Profit Margin	-97.99%	↑ 7.24%

	FY24	Y/Y Change
Revenue	$145.2M	↓ 0.55%
Net Income	$-76.4M	↓ 46.6%
Net Profit Margin	-52.62%	↑ 45.37%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$33.1M	↓ 1.84%
Net Income	$-37.4M	↓ 10.7%
Net Profit Margin	-112.79%	↑ 11.18%

	Q2 FY24	Q/Q Change
Revenue	$42.8M	↑ 29.16%
Net Income	$23.8M	↓ 163.68%
Net Profit Margin	55.61%	↑ 168.4%

	Q3 FY24	Q/Q Change
Revenue	$38.8M	↓ 9.36%
Net Income	$-32.1M	↓ 234.8%
Net Profit Margin	-82.7%	↓ 138.31%

	Q4 FY24	Q/Q Change
Revenue	$30.5M	↓ 21.25%
Net Income	$-30.8M	↓ 4.03%
Net Profit Margin	-100.78%	↓ 18.08%

	Q1 FY25	Q/Q Change
Revenue	$30.0M	↓ 1.73%
Net Income	$-23.5M	↓ 23.78%
Net Profit Margin	-78.17%	↑ 22.61%

	Q2 FY25	Q/Q Change
Revenue	$37.9M	↑ 26.37%
Net Income	$-37.3M	↑ 58.78%
Net Profit Margin	-98.22%	↓ 20.05%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$38.5M	↓ 129.37%

	FY20	Y/Y Change
Profit	$105.4M	↑ 173.81%

	FY21	Y/Y Change
Profit	$206.4M	↑ 95.88%

	FY22	Y/Y Change
Profit	$151.9M	↓ 26.43%

	FY23	Y/Y Change
Profit	$141.1M	↓ 7.09%

	FY24	Y/Y Change
Profit	$139.2M	↓ 1.32%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$31.1M	↓ 3.27%

	Q2 FY24	Q/Q Change
Profit	$41.2M	↑ 32.44%

	Q3 FY24	Q/Q Change
Profit	$37.5M	↓ 9.09%

	Q4 FY24	Q/Q Change
Profit	$29.2M	↓ 22.07%

	Q1 FY25	Q/Q Change
Profit	$28.7M	↓ 1.7%

	Q2 FY25	Q/Q Change
Profit	$36.9M	↑ 28.43%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-190.8M	↑ 19.93%
Investing Cash Flow	$78.5M	↓ 172.87%
Financing Cash Flow	$124.3M	↓ 60.68%

	FY20	Y/Y Change
Operating Cash Flow	$-160.2M	↓ 16.03%
Investing Cash Flow	$-53.7M	↓ 168.43%
Financing Cash Flow	$172.1M	↑ 38.44%

	FY21	Y/Y Change
Operating Cash Flow	$-107.1M	↓ 33.15%
Investing Cash Flow	$141.8M	↓ 364.21%
Financing Cash Flow	$73.6M	↓ 57.2%

	FY22	Y/Y Change
Operating Cash Flow	$-149.6M	↑ 39.62%
Investing Cash Flow	$-104.3M	↓ 173.5%
Financing Cash Flow	$193.7M	↑ 163.06%

	FY23	Y/Y Change
Operating Cash Flow	$-92.7M	↓ 38.0%
Investing Cash Flow	$7.9M	↓ 107.62%
Financing Cash Flow	$1.1M	↓ 99.42%

	FY24	Y/Y Change
Operating Cash Flow	$-127.5M	↑ 37.49%
Investing Cash Flow	$95.5M	↑ 1102.43%
Financing Cash Flow	$41.6M	↑ 3605.16%

Q2 FY24

Q3 FY24

Q4 FY24

Q2 FY25

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-38.5M	↓ 11.95%
Investing Cash Flow	$51.3M	↑ 133.65%
Financing Cash Flow	$41.0M	-

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-19.5M	↓ 49.47%
Investing Cash Flow	$7.5M	↓ 85.42%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-25.8M	↑ 32.68%
Investing Cash Flow	$14.8M	↑ 97.98%
Financing Cash Flow	$680.0K	-

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-18.7M	↓ 52.04%
Investing Cash Flow	$18.3M	↑ 19.6%
Financing Cash Flow	$356.0K	-

Karyopharm Therapeutics Technicals Summary

Sell

Neutral

Buy

Karyopharm Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Karyopharm Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Karyopharm Therapeutics Inc	46.44%	-28.66%	-48.27%	-92.56%	-97.09%
Regeneron Pharmaceuticals, Inc.	4.66%	-17.37%	-50.86%	-2.39%	-3.46%
Beone Medicines Ltd	7.62%	21.35%	57.45%	78.28%	25.05%
Vertex Pharmaceuticals Incorporated	-15.87%	-17.97%	-18.14%	35.67%	45.07%
Alnylam Pharmaceuticals, Inc.	38.16%	82.49%	68.79%	112.36%	238.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Karyopharm Therapeutics Inc	NA	NA	-0.15	-8.7	-8.91	-0.45	NA	-27.63
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Karyopharm Therapeutics Inc	Buy	$52.2M	-97.09%	NA	-90.02%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-3.46%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	25.05%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	45.07%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	238.79%	NA	-12.96%

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Organization	Karyopharm Therapeutics
Employees	279
CEO	Mr. Richard A. Paulson M.B.A.
Industry	Health Technology

Key Management of Karyopharm Therapeutics Inc

Name	Title
Mr. Richard A. Paulson M.B.A.	President, CEO & Director
Ms. Sohanya Cheng M.B.A.	Executive VP, Chief Commercial Officer & Head of Business Development
Dr. Reshma Rangwala M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Research
Dr. Mansoor Raza Mirza M.D.	Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Dr. Sharon Shacham M.B.A., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board
Ms. Lori A. Macomber CPA	EVP, CFO & Treasurer
Ms. Kristin Abate	VP, Chief Accounting Officer & Assistant Treasurer
Mr. Brendan Twohig Strong	SVP of Investor Relations & Corporate Communications
Mr. Michael J. Mano J.D.	Senior VP, General Counsel & Secretary
Mr. James Accumanno J.D.	Chief Compliance Officer

Important FAQs about investing in KPTI Stock from India :

What is Karyopharm Therapeutics share price today?

Karyopharm Therapeutics share price today is $6.30 as on August 23, 2025 at 1:29 AM IST at the close of the market. Karyopharm Therapeutics share today touched a day high of $6.45 and a low of $6.10.

What is the 52 week high and 52 week low for Karyopharm Therapeutics share?

Karyopharm Therapeutics share touched a 52 week high of $16.95 and a 52 week low of $3.51. Karyopharm Therapeutics stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $6.30, lower by 62.83% versus the 52 week high.

How to invest in Karyopharm Therapeutics Stock (KPTI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Karyopharm Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Karyopharm Therapeutics Shares that will get you 0.2381 shares as per Karyopharm Therapeutics share price of $6.30 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Karyopharm Therapeutics Stock (KPTI) from India?

Indian investors can start investing in Karyopharm Therapeutics (KPTI) shares with as little as ₹87.521 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Karyopharm Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Karyopharm Therapeutics share’s latest price of $6.30 as on August 23, 2025 at 1:29 AM IST, you will get 1.5873 shares of Karyopharm Therapeutics. Learn more about fractional shares .

What are the returns that Karyopharm Therapeutics has given to Indian investors in the last 5 years?

Karyopharm Therapeutics stock has given -97.09% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?